Department of Nephrology, Sisli Etfal Research and Educational Hospital, Istanbul, Turkey.
Nefrologia. 2012 May 14;32(3):335-42. doi: 10.3265/Nefrologia.pre2012.Jan.11143. Epub 2012 Apr 17.
The aim of this study is to investigate the mortality and the factors which may affect it in patients who were transferred to peritoneal dialysis (PD) from hemodialysis (HD), compared to patients assigned to PD as first-line therapy.
A total of 322 patients treated with PD between 2001 and 2010 were evaluated retrospectively. Twenty three patients were excluded and the data of remaining 299 patients (167F, mean follow up time 38.5±26.8 months, mean age 44.7±15.9 years) were evaluated. Patients were separated into two groups according to their HD history. Group 1 and group 2 consisted of patients with (n=48) and without (n=251) a history of prior HD, respectively. Socio-demographic characteristics such as who helped administer the PD and the preference of patients (compulsory vs their preference) were obtained from the patient records. The clinical data obtained during the last clinical evaluation before the initiation of PD (blood pressure, daily urine volumes, daily ultrafiltration amounts and laboratory parameters) were recorded. Additional systemic diseases and information about the etiologies of the end stage renal disease (ESRD) of all patients were recorded. Frequencies of the infectious complications were recorded. Patient and technique survival were investigated and compared between groups.
In group 1, the patients were older and had less urine amounts (p=0.028 and 0.041 respectively). Thirty five patients (70%) and 25 patients (9.3%) have been transferred to PD due to vascular problems in group 1 and 2, respectively (p<0.001). In group 1, 37 (74%) patients were carrying out PD treatment by themselves, compared to 222 (88.4%) patients in group 2 (p=0.016). Incidences of peritonitis and catheter exit site/tunnel infection attacks were found 24.9±26.8 and 27.2±26.5 patient-months in group 1, and 27.4±22.4 and 33.4±24.5 patient-months in group 2, respectively (p=0.50 and 0.12). In group 1, twenty three patients have death and 2 patients have discontinued the treatment due to transplantation. In group 2, 174 patients have discontinued the treatment (55 patients have died, 80 patients have been switched to hemodialysis and 39 patients have received renal transplantation). There were significant differences between groups according to the last condition (p<0.001). Mean patient survival were found 22.9±4.2 and 55.5±2.8 patient-months in group 1 and group 2, respectively. The patient survival rates by Kaplan-Meier analysis were 50%, 40.9%, 27.3% and 9.1% at 1, 2, 3, and 4 years in group 1 and 90.9%, 81.6%, 73.9%, 64.9% and 53.1% at 1, 2, 3, 4 and 5 years in group 2, respectively. The mortality rate is higher in patients who have undergone HD before PD compared without HD history (log rank:<0.001). In the Cox proportional hazards model analysis, preference of PD (RR: 7.72, p<0.001), presence of diabetes (RR: 2.26, p=0.01), pretreatment serum albumin level (RR: 0.37, p<0.001) and catheter exit size infection attacks (RR:0.34, p=0.01) were identified as predictors of mortality.
Our data show that mortality in patients transferred to PD from HD was higher than in patients undergoing PD as first-line therapy. Compulsory choice such as vascular access problems and social factors were the most important causes of increasing mortality in patients transferred to PD from HD.
本研究旨在比较从血液透析(HD)转为腹膜透析(PD)的患者与首次接受 PD 治疗的患者的死亡率及其影响因素。
回顾性评估了 2001 年至 2010 年间接受 PD 治疗的 322 例患者。排除 23 例患者,评估剩余 299 例患者(167 例女性,平均随访时间 38.5±26.8 个月,平均年龄 44.7±15.9 岁)的数据。根据患者的 HD 病史将患者分为两组。第 1 组和第 2 组分别包括有(n=48)和无(n=251)HD 病史的患者。从患者记录中获得了帮助管理 PD 的人员和患者的偏好(强制性与他们的偏好)等社会人口统计学特征。记录 PD 开始前最后一次临床评估时获得的临床数据(血压、每日尿量、每日超滤量和实验室参数)。记录所有患者的其他系统性疾病和终末期肾病(ESRD)病因信息。记录感染性并发症的频率。调查并比较两组患者的生存率。
第 1 组患者年龄较大,尿量较少(p=0.028 和 0.041)。第 1 组 35 例(70%)和 25 例(9.3%)患者因血管问题转为 PD,第 2 组分别为 35 例(70%)和 25 例(9.3%)(p<0.001)。第 1 组中,有 37 例(74%)患者自行进行 PD 治疗,而第 2 组中 222 例(88.4%)患者由他人协助(p=0.016)。第 1 组中腹膜炎和导管出口/隧道感染的发生率分别为 24.9±26.8 和 27.2±26.5 患者月,第 2 组分别为 27.4±22.4 和 33.4±24.5 患者月(p=0.50 和 0.12)。第 1 组中有 23 例患者死亡,2 例患者因移植而停止治疗。第 2 组中有 174 例患者停止治疗(55 例死亡,80 例转为血液透析,39 例接受肾移植)。根据最后情况,两组之间存在显著差异(p<0.001)。第 1 组和第 2 组患者的平均生存率分别为 22.9±4.2 和 55.5±2.8 患者月。Kaplan-Meier 分析显示,第 1、2、3 和 4 年时第 1 组的生存率分别为 50%、40.9%、27.3%和 9.1%,第 2 组的生存率分别为 90.9%、81.6%、73.9%、64.9%和 53.1%。与无 HD 病史的患者相比,HD 后转为 PD 的患者死亡率更高(对数秩:<0.001)。Cox 比例风险模型分析显示,PD 偏好(RR:7.72,p<0.001)、糖尿病存在(RR:2.26,p=0.01)、预处理血清白蛋白水平(RR:0.37,p<0.001)和导管出口大小感染发作(RR:0.34,p=0.01)是死亡率的预测因素。
我们的数据表明,从 HD 转为 PD 的患者的死亡率高于首次接受 PD 治疗的患者。血管通路问题和社会因素等强制性选择是导致从 HD 转为 PD 的患者死亡率增加的最重要原因。